I’s dotted and t’s crossed on BresaGen restructure
26 May, 2004 by Renate KrelleThe administrators of Adelaide biotech BresaGen (ASX:BGN) today formalised the agreement the company has made with Queensland-based public unlisted biotech company CBio by executing a Deed of Company Arrangement for the restructure of the company.
EU patent snatchback won't affect GTG: Jacobson
21 May, 2004 by Graeme O'NeillThe European Patent Office's decision to revoke a key patent on a breast cancer test owned by Utah-based Myriad Genetics will not prevent Myriad's Australian licensee, Genetic Technologies Ltd (ASX: GTG) providing the test in Australia and Asia.
Victorians get $60 million for innovation infrastructure
21 May, 2004 by Melissa TrudingerThe Victorian State Government will fund another round of the Science Technology Innovation Infrastructure Grants program (STII), providing $60 million to supports biomedical, environmental, agricultural, manufacturing and ICT infrastructure projects.
XCeed lists on ASX at a premium
19 May, 2004 by Melissa TrudingerXceed Biotechnology has listed on the ASX (ASX: XBL) at a premium to its placement price of AUD$0.20. At the time of writing the telco turned biotech company, was trading at $0.26, down almost 20 per cent from its opening price of $0.30.
Brains for hire: Bio21 supports undergraduate lab-jobs program
18 May, 2004 by Melissa TrudingerThe Undergraduate Research Opportunities Program (UROP) has been re-launched as a Bio21 initiative following the receipt of $90,000 over three years from the Victorian State government Department of Industry, Innovation and Regional Development's Office of Science and Technology for the program.
Australia ‘most prominent’ in Asia-Pacific biotechnology, but times may be changing
13 May, 2004 by Renate KrelleThe Australian biotechnology industry comes sixth in the world when ranked by number of biotech companies, according to ‘On the Threshold’, an Ernst and Young report released today.
BIO 2004: Greenbacks and tax traps
07 May, 2004 by Melissa TrudingerDon't think it's impossible for Australian companies to attract venture capital investment from the US, but their chances of success will be much greater if they can also prove that they can attract Australian VC.
Government unveils $5.3 billion science and innovation program
06 May, 2004 by Renate KrellePrime Minister John Howard today announced a $5.3 billion package for science and innovation, the second tranche of funding under the Backing Australia’s Ability program.
New directors at Proteome Systems in IPO lead-up
04 May, 2004 by Graeme O'NeillSydney-based biotech Proteome Systems has appointed two non-executive directors as it prepares for a long-awaited IPO.
Bye-bye biodollars: ASX code calls for realistic biotech reporting
04 May, 2004 by Renate KrelleTechnospeak and blue sky 'biodollars' will be frowned upon and plain English encouraged under the Australian Stock Exchange's new biotechnology reporting code.
Peptech, Agenix to merge
29 April, 2004 by Melissa TrudingerSydney-based biotech Peptech (ASX:PTD) and Brisbane-based Agenix (ASX:AGX) have revealed plans to merge, creating one of Australia's largest biotechnology companies with a market capitalisation of AUD$400 million.
WEHI head gets pontifical appointment
23 April, 2004 by Susan WilliamsonProf Suzanne Cory, director of the Walter and Eliza Hall Institute, has been appointed a member of the Pope’s scientific advisory council, the Pontifical Academy of Sciences.
WA's BioPharmica readies for float
22 April, 2004 by Melissa TrudingerPerth-based investment company Grandbridge (ASX:GBA) is preparing to list its biotechnology business BioPharmica on the ASX.
Ignore the fashion victims and know your strengths, says Maxygen chief
16 April, 2004 by Renate KrelleIdiosyncratic researchers who are stubbornly out of step with the fashions of science may be among Australia's more valuable assets when it comes to building a successful life science industry, an Australian Venture Capital Association briefing in Sydney heard today.
SA, Germany in biotech start-up pact
14 April, 2004 by Graeme O'NeillBio Innovation South Australia has a special offer for Australian biotech companies eying the lucrative European market: set up in SA, and take a free one-month working holiday to Germany to court potential business and research partners and clients.
